These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7758353)

  • 1. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone.
    Iwasaki H; Miyazaki S; Tsuji A; Yamaguchi K; Goto S
    Chemotherapy; 1995; 41(2):100-12. PubMed ID: 7758353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
    Baquero F; Cantón R
    J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.
    Imada T; Miyazaki S; Nishida M; Yamaguchi K; Goto S
    Antimicrob Agents Chemother; 1992 Mar; 36(3):573-9. PubMed ID: 1320364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
    Masuda N; Takahashi Y; Otsuki M; Ibuki E; Miyoshi H; Nishino T
    Antimicrob Agents Chemother; 1996 May; 40(5):1201-7. PubMed ID: 8723467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activity of Q-35, a new fluoroquinolone.
    Ito T; Otsuki M; Nishino T
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1708-14. PubMed ID: 1329626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
    Ravizzola G; Pizzi R; Pirali F; Turano A
    J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.
    Park HS; Kim HJ; Seol MJ; Choi DR; Choi EC; Kwak JH
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2261-4. PubMed ID: 16723601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].
    Imamori K; Asaoka T; Matsumoto M; Maebashi K; Matsuda H; Tahara Y
    Jpn J Antibiot; 1996 Mar; 49(3):264-72. PubMed ID: 8935122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.
    Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Nukiwa T
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1767-8. PubMed ID: 10390240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.
    Montanari MP; Mingoia M; Varaldo PE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3616-22. PubMed ID: 11709353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate.
    Yamaguchi K
    J Infect Chemother; 2001 Dec; 7(4):205-17. PubMed ID: 11810586
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.